DE222 Honoree: Hervé Hoppenot

Title: Chairman & CEO

Workplace: Incyte

Alma Mater: ESSEC Business School

Herve Hoppenot

Boards: Incyte, PhRMA

Q&A: Favorite thing about Delaware? “Incyte has called Delaware home for over 20 years, What makes Delaware truly unique is its vibrant and diverse business community that – even as it grows – remains tightly knit. Over the years, the Delaware community

Taking the helm of Incyte in 2014 after a career at pharmaceutical giant Novartis, Hervé Hoppenot has led the Wilmington-based drug development company to new heights. Building upon Incyte’s billion-dollar drug Jakafi, Hoppenot has overseen Incyte’s move into the dermatological sector, developing Opzelura, the first drug approved to treat vitiligo. With that success, Incyte is investing heavily to grow its product development in dermatology and autoimmunity, with plans to address other more rare disorders. The company’s annual revenue has grown nearly 600% since Hoppenot took over, and it has invested heavily in its Delaware headquarters, adding staff and facilities, with plans to further grow in the near future with a major expansion project at the former Friends School campus.